Study design and subject baseline characteristics in the ADVANCE Study: Effects of cinacalcet on vascular calcification in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 25, Issue 6, 2010, Pages 1916-1923

  Floege, Jürgen ^a   Raggi, Paolo ^b   Block, Geoffrey A ^c   Torres, Pablo Urena ^d   Csiky, Botond ^e   Naso, Agostino ^f   Nossuli, Kaldin ^g   Moustafa, Moustafa ^h   Goodman, William G ⁱ   Lopez, Nicole ⁱ   Downey, Gerry ^j   Dehmel, Bastian ⁱ   Chertow, Glenn M ^k  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Denver Nephrology   (United States)

^d Clinique du Landy   (France)

^e UNIVERSITY OF PÉCS   (Hungary)

^f UNIVERSITY OF PADOVA   (Italy)

^g Washington Nephrology Associates   (United States)

^h South Carolina Nephrology and Hypertension   (United States)

ⁱ AMGEN INC   (United States)

^j AMGEN LTD   (United Kingdom)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Calcification; Cinacalcet; Haemodialysis; Study design; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CINACALCET; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL;

ADULT; AGED; ARTERY CALCIFICATION; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; HEMODIALYSIS; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; STUDY DESIGN;

AGED; CALCINOSIS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; RENAL DIALYSIS; VASCULAR DISEASES; VITAMIN D;

EID: 77952570750     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp762     Document Type: Article

References (30)

1. Kramer H, Toto R, Peshock R et al. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol 2005; 16: 507-513 (Pubitemid 41725148)
2. Braun J, Oldendorf M, Moshage W et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394-401
3. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942
4. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
5. Ketteler M, Schlieper G, Floege J. Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 2006; 47: 1027-1034
6. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2964
7. Shanahan CM. Vascular calcification. Curr Opin Nephrol Hypertens 2005; 14: 361-367
8. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
9. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral cal-cimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-807
10. Chertow GM, Blumenthal S, Turner S et al. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium × phosphate. Clin J Am Soc Nephrol 2006; 1: 305-312
11. Sterrett JR, Strom J, Stummvoll HK et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 2007; 68: 10-17
12. Block GA, Zeig S, Sugihara J et al. Combined therapy with cinacal-cet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008; 23: 2311-2318
13. Fishbane S, Shapiro WB, Corry DB et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyper-parathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3: 1718-1725
14. Messa P, Macario F, Yaqoob M et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3: 36-45
15. Urena P, Jacobson SH, Zitt E et al. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice\the ECHO observational study. Nephrol Dial Transplant 2009; 24: 2852-2859
16. Agatston AS, Janowitz WR, Hildner FJ et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-832
17. Callister TQ, Cooil B, Raya SP et al. Coronary artery disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method. Radiology 1998; 208: 807-814
18. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
19. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824
20. Bellasi A, Kooienga L, Block GA et al. How long is the warranty period for nil or low coronary artery calcium in patients new to he-modialysis? J Nephrol 2009; 22: 255-262
21. Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol 2004; 24: 1272-1277
22. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701
23. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38
24. Mizobuchi M, Finch JL, Martin DR et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715
25. Milliner DS, Zinsmeister AR, Lieberman E et al. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38: 931-936
26. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620
27. Henley C, Davis J, Miller G et al. The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. Eur J Pharmacol 2009; 616: 306-313
28. Ivanovski O, Nikolov IG, Joki N et al. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE(-/-)) mice. Atherosclerosis 2009; 205: 55-62
29. Lopez I, Mendoza FJ, Guerrero F et al. The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. Am J Physiol Renal Physiol 2009; 296: F1376-F1385
30. Chertow GM, Pupim LB, Block GA et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007; 2: 898-905